NL2038973A - Bi-functional glutathione synthase mutant and application thereof - Google Patents
Bi-functional glutathione synthase mutant and application thereof Download PDFInfo
- Publication number
- NL2038973A NL2038973A NL2038973A NL2038973A NL2038973A NL 2038973 A NL2038973 A NL 2038973A NL 2038973 A NL2038973 A NL 2038973A NL 2038973 A NL2038973 A NL 2038973A NL 2038973 A NL2038973 A NL 2038973A
- Authority
- NL
- Netherlands
- Prior art keywords
- cysteine
- glutathione
- mutant
- glutathione synthase
- gsh
- Prior art date
Links
- 108010036164 Glutathione synthase Proteins 0.000 title claims abstract description 66
- 102100034294 Glutathione synthetase Human genes 0.000 title claims abstract description 66
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 160
- 229960003180 glutathione Drugs 0.000 claims abstract description 81
- 238000004519 manufacturing process Methods 0.000 claims abstract description 50
- 108010024636 Glutathione Proteins 0.000 claims abstract description 15
- 238000006243 chemical reaction Methods 0.000 claims description 52
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 52
- 235000018417 cysteine Nutrition 0.000 claims description 52
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 48
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 claims description 34
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 34
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 32
- 210000004027 cell Anatomy 0.000 claims description 32
- 238000006555 catalytic reaction Methods 0.000 claims description 27
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 20
- 150000001413 amino acids Chemical group 0.000 claims description 20
- 238000003786 synthesis reaction Methods 0.000 claims description 17
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004471 Glycine Substances 0.000 claims description 16
- 235000013922 glutamic acid Nutrition 0.000 claims description 16
- 239000004220 glutamic acid Substances 0.000 claims description 16
- 244000005700 microbiome Species 0.000 claims description 13
- 230000015572 biosynthetic process Effects 0.000 claims description 12
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 9
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 claims description 9
- 235000019982 sodium hexametaphosphate Nutrition 0.000 claims description 9
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 239000012620 biological material Substances 0.000 claims description 5
- 230000014509 gene expression Effects 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- 230000003197 catalytic effect Effects 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 3
- 108020004511 Recombinant DNA Proteins 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 239000013600 plasmid vector Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 abstract description 42
- 230000009466 transformation Effects 0.000 abstract description 33
- 230000035772 mutation Effects 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 241000194017 Streptococcus Species 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 60
- 230000001580 bacterial effect Effects 0.000 description 17
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- 241000194023 Streptococcus sanguinis Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 108020000161 polyphosphate kinase Proteins 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 10
- 229960001153 serine Drugs 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 108010075344 Tryptophan synthase Proteins 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 230000008569 process Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000009776 industrial production Methods 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229910000397 disodium phosphate Inorganic materials 0.000 description 3
- 235000019800 disodium phosphate Nutrition 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 3
- 229960001327 pyridoxal phosphate Drugs 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 101000889837 Aeropyrum pernix (strain ATCC 700893 / DSM 11879 / JCM 9820 / NBRC 100138 / K1) Protein CysO Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PABVKUJVLNMOJP-WHFBIAKZSA-N Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(O)=O PABVKUJVLNMOJP-WHFBIAKZSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- -1 thiol compound Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
- C12Y603/02—Acid—amino-acid ligases (peptide synthases)(6.3.2)
- C12Y603/02003—Glutathione synthase (6.3.2.3)
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (10)
1. Glutathionsynthasemutant, gekenmerkt doordat deze gemuteerd is op de volgende plaatsen op basis van een aminozuursequentie getoond in SEQ ID NO:1; van Rnaar E gemuteerd op de 184e plaats, van H naar F gemuteerd is op de 325e plaats, van N naar I of L gemuteerd is op de 329e positie, en van Q naar D gemuteerd is op de 329e plaats.
2. Nucleinezuurmolecule die codeert voor een mutant volgens conclusie 1.
3. Biologisch materiaal dat de nucleinezuurmolecuul volgens conclusie 2 bevat, gekenmerkt doordat het een recombinant DNA, een expressiecassette, een transposon, een plasmide vector, een virale vector of een gemanipuleerde bacterie is.
4. Recombinant micro-organisme, gekenmerkt doordat het verkregen is door de introductie van een nucleïnezuurmolecule volgens conclusie 2 in het micro-organisme via een plasmide of het integreren in het chromosoom van het micro-organisme via genetische manipulatie.
5. Gebruik van de glutathionsynthasemutant volgens conclusie 1, het nucleïnezuurmolecuul volgens conclusie 2, het biologisch materiaal volgens conclusie 3 of het recombinante micro-organisme volgens conclusie 4 bij de productie van glutathion.
6. Werkwijze voor het synthetiseren van glutathion middels in vitro katalyse synthese van glutathion, gekenmerkt door het gebruik van de glutathionsynthasemutant volgens conclusie 1.
7. Werkwijze volgens conclusie 6, gekenmerkt doordat deze de volgende stappen omvat: (1) het kweken van een micro-organisme volgens conclusie 4 om een glutathionsynthasemutant tot expressie te brengen; (2) het uitvoeren van celdisruptie op de kweek, waarbij de daardoor verkregen celdisruptieoplossing een reactieve-enzymoplossing is die de glutathionsynthasemutant bevat; en (3) het gebruiken van de reactieve-enzymoplossing om de reactie van glutaminezuur, cysteine, glycine en ATP om glutathion te synthetiseren, te katalyseren.
8. Werkwijze volgens conclusie 7, gekenmerkt doordat de samenstelling van het katalytische systeem van stap (3) geselecteerd wordt uit een van de volgende groepen: (1) glutaminezuur, cysteine, glycine, ATP, magnesiumchloride en een reactie- enzymoplossing die de glutathionsynthasemutant bevat; en (it) glutaminezuur, cysteine, glycine, ATP, natriumhexametafosfaat, polyfosfokinase (PPK), magnesiumchloride en een reactieve-enzymoplossing die de glutathionsynthasemutant bevat.
9. Werkwijze volgens conclusie 7 of 8, gekenmerkt doordat de cysteine zuivere cysteine of ongezuiverde cysteine is.
10. Werkwijze volgens conclusie 9, gekenmerkt doordat de ongezuiverde cysteine een serine in cysteine omzettingsreactieoplossing is of een cysteinefermentatieoplossing die verkregen is door fermentatie van een cysteineproducerende stam.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410627257.3A CN118207172B (zh) | 2024-05-21 | 2024-05-21 | 双功能谷胱甘肽合酶突变体及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL2038973A true NL2038973A (en) | 2024-12-17 |
Family
ID=91454703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2038973A NL2038973A (en) | 2024-05-21 | 2024-10-31 | Bi-functional glutathione synthase mutant and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN118207172B (nl) |
| NL (1) | NL2038973A (nl) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119776294B (zh) * | 2025-01-21 | 2025-10-03 | 浙江工业大学 | 谷胱甘肽双功能合成酶突变体及其在催化合成谷胱甘肽中的应用 |
| CN120758588A (zh) * | 2025-07-18 | 2025-10-10 | 中国农业科学院饲料研究所 | L-谷胱甘肽双功能合成酶及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107267471B (zh) * | 2017-07-05 | 2020-07-14 | 湖南福来格生物技术有限公司 | 双功能谷胱甘肽合成酶突变体、核苷酸序列及其制备方法和应用 |
| JP7124338B2 (ja) * | 2018-02-27 | 2022-08-24 | 味の素株式会社 | 変異型グルタチオン合成酵素、及び、γ－グルタミルバリルグリシンの製造法 |
| CN109593735B (zh) * | 2019-01-26 | 2019-10-29 | 珠海天香苑生物科技发展股份有限公司 | 双功能谷胱甘肽合成酶的突变体及其在谷胱甘肽合成中的应用 |
| WO2022131323A1 (ja) * | 2020-12-17 | 2022-06-23 | 株式会社カネカ | 有用物質を製造する微生物、および製造方法 |
| CN117586968A (zh) * | 2022-08-16 | 2024-02-23 | 武汉启瑞药业有限公司 | 一种双功能谷胱甘肽合成酶的高活性突变体的设计与筛选方法、突变体及其应用 |
-
2024
- 2024-05-21 CN CN202410627257.3A patent/CN118207172B/zh active Active
- 2024-10-31 NL NL2038973A patent/NL2038973A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118207172B (zh) | 2024-08-09 |
| CN118207172A (zh) | 2024-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL2038973A (en) | Bi-functional glutathione synthase mutant and application thereof | |
| CN107916283B (zh) | 一种烟酰胺的生产工艺 | |
| CN104531629B (zh) | 一种提高aa‑2g转化率的环糊精葡萄糖基转移酶突变体 | |
| CN108467860B (zh) | 一种高产γ-氨基丁酸的方法 | |
| CN110387379B (zh) | 一种用于生产谷胱甘肽的重组大肠杆菌的混合培养工艺及其应用 | |
| CN106868030B (zh) | 重组载体、含有其的工程菌及在产α-酮戊二酸的应用 | |
| CN112831488A (zh) | 一种谷氨酸脱羧酶及γ-氨基丁酸高产菌株 | |
| CN115704045B (zh) | 一种生产单细胞蛋白的方法及碳固定系统 | |
| CN112625993B (zh) | 微生物转化法制备α-酮戊二酸 | |
| CN113151378A (zh) | 制备烟酸或其衍生物的核苷、烟酸腺嘌呤二核苷酸、烟酸单核苷酸的方法、酶组合物及应用 | |
| CN116769749A (zh) | 多聚磷酸盐激酶及其偶联谷胱甘肽双功能酶生产谷胱甘肽的方法 | |
| CN113355367B (zh) | 酮酸还原酶在合成手性芳香2-羟酸中的应用 | |
| CN120574905A (zh) | 双酶在一步法制备l-硒甲基硒代半胱氨酸中的应用 | |
| CN117683760B (zh) | 色氨酸合酶突变体及其在制备半胱氨酸和胱氨酸中的应用 | |
| CN117778281A (zh) | 一种重组基因工程菌及(r)-2-(1-氨基乙基)-4-氟苯酚的制备方法 | |
| CN117866866A (zh) | 一种利用富马酸生产依克多因的重组大肠杆菌及其构建方法和应用 | |
| CN117305208A (zh) | 一种高产β-烟酰胺单核苷酸的工程菌及其构建方法和应用 | |
| WO2024197480A1 (zh) | 一种利用酰胺酶合成右旋酮洛芬的方法 | |
| WO2022217694A1 (zh) | 制备β-烟酰胺单核苷酸的方法、酶组合物及其应用 | |
| CN118374468B (zh) | 一种转氨酶突变体及其在(s)-苯并二氢吡喃-4-胺制备上的应用 | |
| CN118599802B (zh) | 一种转氨酶、其制备方法、其应用，编码转氨酶的基因，重组质粒，重组菌，制备(s)-3-氨基丁酸的方法 | |
| CN114934037B (zh) | 用于生产3-氨基丙腈的天冬氨酸酶突变体 | |
| CN119101636A (zh) | 一种用于生产麦角硫因的菌株、生物材料、生产方法及应用 | |
| CN117757865A (zh) | 一种多酶偶联转化制备l-半胱氨酸的方法 | |
| CN116987650A (zh) | 一种产四氢嘧啶的嗜甲烷工程菌及其构建方法和应用 |